Distinguished in Hemorrhagic Proctocolitis

Masakazu Nagahori

Tokyo, JP 
Distinguished in Hemorrhagic Proctocolitis
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Masakazu Nagahori practices in Tokyo, Japan. Mr. Nagahori is rated as a Distinguished expert by MediFind in the treatment of Hemorrhagic Proctocolitis. His top areas of expertise are Viral Gastroenteritis, Colitis, Ulcerative Colitis, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 73 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 33 articles and participated in 1 clinical trial in the study of Hemorrhagic Proctocolitis.

Gender
Male

Locations

Tokyo, Japan
Other Locations
Yushima, Japan
Minato, 1050004, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects With Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period for a Total of up to 52 Weeks
A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects With Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period for a Total of up to 52 Weeks
Enrollment Status: Terminated
Publish Date: October 06, 2025
Intervention Type: Biological
Study Drug: Darvadstrocel
Study Phase: Phase 3
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Completed
Publish Date: March 26, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
View 1 Less Clinical Trial

73 Total Publications

A Multicenter Observational Study for the Establishment of Novel Severity Criteria Including Endoscopic Evaluation for Intestinal Behçet's Disease.
A Multicenter Observational Study for the Establishment of Novel Severity Criteria Including Endoscopic Evaluation for Intestinal Behçet's Disease.
Journal: Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
Published: April 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Nagahori's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile